Hadassah University Medical Center Clinical Trial Reveals Success of New Treatment Combination for Post-Traumatic Stress Disorder
Results of a clinical trial at the Hadassah University Medical Center indicate that Deep Transcranial Magnetic Stimulation (TMS) can be an effective treatment for Post-Traumatic Stress Disorder (PTSD) when combined with exposure to trauma memory cues.
TMS is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. "This study," relates Principal Investigator Dr. Moshe Isseries of Hadassah's Department of Psychiatry, "was the first of its kind designed to test the effectiveness of TMS on people with severe or resistant PTSD." Only a few studies, he says, "have been conducted using magnetic stimulation and none using the combination of magnetic stimulation and exposure to trauma memory."
The trial involved an innovative device, developed by the Israeli company, Brainsway Ltd, which stimulates extensive areas deeper in the cortex. The 26 patients in the trial were divided into three groups: One group was treated using the Deep TMS device together with a brief exposure to trauma cues (reminders of a traumatic event conveyed to the patient through earphones); a second group received Deep TMS treatment with no trauma cues; and a third group received sham stimulation with exposure to trauma cues. All the patients in the study participated in at least 8 sessions, the minimum required for treatment. Only the group that received active Deep TMS with exposure to cues showed a statistically significant improvement. "There was a marked decrease in nightmares and flashbacks and improvement in sleeping, mood, and functioning," Dr. Isseries reports. Follow-up questionnaires yielded similar findings. The improvement remained constant.
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>